Document:

Trimble Navigation Limited Board of Directors Compensation Policy

 Exhibit 10.4 
 Trimble Navigation Limited 
 Board of Directors Compensation Policy 

The following is a schedule of the elements of compensation and expense reimbursement for nonemployee members of the board of directors. This policy is
effective May 3, 2011. 
  

	•	 	 A stock option grant of 15,000 shares under the Trimble 2002 Stock Option Plan upon the initial appointment or election to the board.

  

	•	 	 An additional annual stock option grant of 15,000 shares to be granted to each director upon re-election by the shareholders at Trimble’s Annual
Shareholders’ Meeting. 

  

	•	 	 Options granted to directors are at fair market value on the date of grant and will have a term of seven years, vesting monthly, on a pro-rated basis,
over one year. Vested options are exercisable for 12 months after the individual ceases to be a member of the board, but in no event longer than the regular term of the stock option grant. 

 

	•	 	 An annual cash retainer of $44,000, payable quarterly, commencing with the company’s third fiscal quarter. 

 

	•	 	 A payment of $2,000 for each day in attendance at a board meeting. 

 

	•	 	 A payment of $500 for participation in a telephonic board meeting. 

 

	•	 	 A payment of $1,000 for each board committee meeting attended, that is not held within a day of a board meeting. 

 

	•	 	 A payment of $500 for participation in a telephonic board committee meeting. 

 

	•	 	 A director will be paid a travel and transportation allowance, in lieu of reimbursement for expenses, in accordance with the following schedule:

 $4,000 for travel to a meeting held between 1,000 miles and 3,000 miles from the director’s place of
residence. 
 $15,000 for travel to a meeting held more than 3,000 miles from the director’s place of
residence. 
  

			
	Note:	 	Miles are one-way and will be measured by air miles between airports.
		 	Nickolas W. Vande Steeg will be paid a travel and transportation allowance of $1,500.

  

	•	 	 Reimbursement of travel expenses consistent with Trimble policy for travel to a meeting held less than 1,000 miles from the director’s place of
residence and all necessary travel on Trimble business, other than to attend a board meeting.Exhibit 10.1

 Exhibit 10.1 
 [Company Letter Head] 
 July 25, 2011 

 
 Gregory J. Divis 
 One Corporate Woods Drive 
 Bridgeton, MO 63044 

Dear Greg: 
 This letter agreement shall amend
certain sections (as listed below) of the Employment Agreement dated November 19, 2009 between you and KV Pharmaceutical Company (the “Employment Agreement”). The following amendments shall be made and effective upon approval by the
Board of Directors and your signature below. 
  

	 	1.	Section 1.(a) Employment: Your title shall be changed to President and Chief Executive Officer to reflect your promotion on 11/17/10.

	 	2.	Section 3.(a) Base Salary: Your Base Salary shall be $520,000.00 per annum. (This Base Salary increase will be retro-active to your appointment as President
and Chief Executive Officer effective 11/17/2010). 

	 	3.	Section 3.(c) Annual Cash Incentive: Your target Annual Cash Incentive shall be 60% of your Base Salary. 

	 	4.	Section 3.(f) Vacation: You will be entitled to 25 days of vacation in accordance with the terms of your Employment Agreement.

	 	5.	Section 4.(f)(2) and (3) Payments to the Executive Upon Termination of Employment: These sections are hereby modified to reflect the amount which shall be
equal to two (2) times the sum your current Base Salary plus two (2) times your target Annual Cash Incentive or 60% for each year one is not set. 

	 	6.	You shall be entitled to participate in the Company’s Executive Fleet Program. 

 All capitalized terms used herein but not defined shall have the meaning assigned to them in your Employment Agreement. 
 Sincerely, 
 /s/ Chris Dumm 
 Chris Dumm 
 Director, Human Resources
 ACKNOWLEDGED AND AGREED BY: 
  

	
	/s/ Greg Divis
	Gregory J. Divis

 July 25, 2011Exhibit 10.2

 Exhibit 10.2 
 [Company Letter Head] 
 May 4, 2011 
 Patrick Christmas 
 One Corporate Woods Drive 

Bridgeton, MO 63044
 Dear Patrick: 

Congratulations! We are excited to have you join KV Pharmaceutical Company, and look forward to your arrival on or before 06/1/2011. This letter provides
you with details of your position and benefits, as well as instructions for beginning your new position at KV. 

	 	1.	Title: Vice President, General Counsel 

	 	2.	A bi-weekly salary of $11,538.46 which amounts to $300,000.00, annually. 

	 	3.	Participation in a Performance Bonus with a target of 40% of your annual salary with terms to be developed at a later date. 

	 	4.	Stock Options: Pending Board of Director approval, 40,000 Shares of KV Common Stock in accordance with the terms of the Employee Stock Option Plan.

	 	5.	In accordance with the Company’s vacation policy, for calendar year 2011 you will be eligible for 20 days of vacation, pro-rated based upon date of
hire. In the calendar year after hire you will be eligible for 20 days of vacation. 

	 	6.	Participation in company Fleet Program. 

	 	7.	Executive relocation package to be provided per Company Relocation Policy.

	 	8.	Participation in KV’s medical, dental, disability, and life insurance plans in accordance with the terms of those Plans. 

	 	9.	Participation in KV’s Profit Sharing Plan and 401(k) Plan in accordance with the terms of those Plans. 

	 	10.	In the event that employment is terminated by the Company without Cause the Company shall pay an amount equal to one (1) times the sum of the then current Base
Salary payable over a period of twelve (12) months in equal bi-weekly installments, less deductions as required by law. The company will also provide continued participation in the Company’s plans providing medical, dental, and vision
insurance benefits, as applicable for the twelve (12) month period following the Termination Date. 

 Definition of “Cause”. “Cause” shall mean, during the Term, the occurrence of any of the following: 

(1) commission of a criminal act in respect of the Executive’s employment or conviction of, or plea of guilty or no contest to, a
felony; 

 Patrick Christmas 
  Page
 2
 
  

 (2) willful misconduct, significant dishonesty, gross negligence or breach of fiduciary
duty in respect of the Executive’s employment; 
 (3) continuing neglect or failure of the Executive to perform the
duties reasonably assigned to the Executive by the Company and after notice from the Company of such neglect or failure, the Executive’s failure to cure such neglect or failure within thirty (30) days of such notice, provided that the
Executive shall be provided only one thirty (30) day cure period for the same neglect or failure. 
 A sample of our standard Employment
and Confidential Information Agreement is enclosed for you to read prior to your start date. Your employment is contingent upon the successful completion of a Company-paid drug screen and background verification which you authorized by signing the
“Disclosure to Applicant and Consent to Request Consumer Report Information” form. If you have not yet received information to schedule your physical exam, please contact Traci Shatzer immediately at (314) 645-6600, so that this can
be arranged. 
 During your orientation as a new employee you will be required to sign your Employment and Confidential Information Agreement
and complete various forms, including the federal government I-9 Form. Presentation of appropriate identification documents is required in order for you to begin employment. Please refer to the enclosed list of official documents which are
acceptable by the government as evidence of your identity and eligibility to work in the United States, and bring them with you on your start date. 
 If you have any questions on the enclosures please feel free to give me a call at: 314-645-6600. We look forward to working with you! 
 Sincerely, 
 /s/ Traci Shatzer 
 Traci Shatzer 
 Manager, Human Resources 
 EnclosuresSummary compensation for non-employee directors

 Exhibit 10.1 
 Arena Pharmaceuticals, Inc. 
 Non-Employee Director Compensation

 Equity: 
  

	 	—	 	 Continuing directors and new directors elected at our annual stockholders’ meeting: 48,000 options to purchase shares of our common
stock. The options are granted effective on the date of the annual stockholders’ meeting, and vest in equal monthly installments over one year from the date of grant. With respect to only our June 2011 annual stockholders’ meeting, the
elected directors shall receive 36,000 (instead of 48,000) options to purchase shares of our common stock. 

  

	 	—	 	 New directors appointed or elected other than at our annual stockholders’ meeting: A prorated amount of the annual 48,000 options to
purchase shares of our common stock determined by multiplying the 48,000 annual amount by a fraction, the numerator of which is the number of months until the one-year anniversary of the most recent annual stockholders’ meeting and the
denominator of which is 12. For example, if a new director is appointed in January and the prior year’s annual stockholders’ meeting occurred in June, the new director would be granted 5/12 of 48,000 options, or 20,000 options.

 The options are granted effective on the most recent annual stockholders’ meeting’s monthly
anniversary date following the month of the director’s appointment or election, and vest in equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) beginning on the grant date and ending on the one-year
anniversary of the most recent annual stockholders’ meeting. For example, if a new director is appointed in January and the prior year’s annual stockholders’ meeting occurred on June 13th, the new director would be granted 20,000
options on February 13th, and 4,000 options would vest on the 13th of February, March, April, May and June. 
 The options are 10-year
options with an exercise price equal to the fair market value of our common stock on the grant date. “Fair market value” on the grant date means the per share closing price of our common stock as reported on the NASDAQ Global Select Market
on the grant date or, if there was no reported closing price on such date, on the last preceding date on which the closing price was reported. 

Except in the case of a director’s death or disability, unvested stock options terminate when the director ceases to be a director. Unless earlier
terminated or expired, vested stock options terminate three years after the director ceases to be a director (or, if applicable, an employee) for any reason other than the director’s death or disability. In the event of a director’s death
or disability, the director’s stock options become fully vested and, unless earlier terminated or expired, terminate three years after the date of the director’s death or disability, as applicable. 

Cash: 
  

	 	—	 	 Annual retainer: Beginning with the third quarter of 2011, $7,500 per quarter, subject to continuing service as a director. For 2011, all
directors will receive the increase in the annual retainer from the previous annual retainer in cash, and such increase will not impact directors’ elections in late 2010 to receive all or a portion of the previous annual retainer in stock
options instead of cash. New directors will receive a prorated amount of the quarterly payment for the quarter within which they are appointed or elected. 

 

	 	—	 	 Additional annual retainer for lead independent director: Beginning with the third quarter of 2011, additional $5,000 per quarter,
subject to continuing service as lead independent director. New lead independent 

	 	 
directors will receive a prorated amount of the quarterly payment for the quarter within which they are appointed to such position. 

 

	 	—	 	 Meeting attendance fees: 

  

	 	—	 	 General: $1,000 

  

	 	—	 	 Exceptions: 

  

	 	—	 	 Audit Chair Meeting Attendance Fee: $3,000 

  

	 	—	 	 Other Chair Meeting Attendance Fee: $2,000 

 In addition, our Board of Directors and the Compensation Committee may authorize additional fees for significant work in informal meetings or for other service to us in the recipient’s capacity as a
director or committee member. Each non-employee director is also entitled to reimbursement for all of such director’s reasonable out-of-pocket expenses incurred in connection with performing Board business. 

Approved on June 13, 2011 

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]